PERS
Paediatric European Risperidone Studies
| Coordinatore | STICHTING KATHOLIEKE UNIVERSITEIT
Organization address
address: GEERT GROOTEPLEIN NOORD 9 contact info |
| Nazionalità Coordinatore | Netherlands [NL] |
| Sito del progetto | http://www.pers-project.com/ |
| Totale costo | 7˙360˙763 € |
| EC contributo | 5˙600˙000 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2009-single-stage |
| Funding Scheme | CP-FP |
| Anno di inizio | 2010 |
| Periodo (anno-mese-giorno) | 2010-05-01 - 2015-04-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
STICHTING KATHOLIEKE UNIVERSITEIT
Organization address
address: GEERT GROOTEPLEIN NOORD 9 contact info |
NL (NIJMEGEN) | coordinator | 811˙360.00 |
| 2 |
ZENTRALINSTITUT FUER SEELISCHE GESUNDHEIT
Organization address
address: Square J 5 contact info |
DE (MANNHEIM) | participant | 455˙400.00 |
| 3 |
ACADEMISCH ZIEKENHUIS GRONINGEN
Organization address
address: Hanzeplein 1 contact info |
NL (GRONINGEN) | participant | 418˙800.00 |
| 4 |
MediServ BV
Organization address
address: De Stadspoort 32 contact info |
NL (Eindhoven) | participant | 411˙830.00 |
| 5 |
UNIVERSITA DEGLI STUDI DI CAGLIARI
Organization address
address: VIA UNIVERSITA 40 contact info |
IT (CAGLIARI) | participant | 372˙460.00 |
| 6 |
UNIVERSITAET ULM
Organization address
address: HELMHOLTZSTRASSE 16 contact info |
DE (ULM) | participant | 368˙960.00 |
| 7 |
SERMES PLANIFICACION
Organization address
address: CALLE RUFINO GONZALEZ 14 contact info |
ES (MADRID) | participant | 352˙305.00 |
| 8 |
Dimensione Ricerca S.r.l.
Organization address
address: Viale dei Parioli 12 contact info |
IT (Rome) | participant | 331˙090.00 |
| 9 |
UNIVERSITY COLLEGE LONDON
Organization address
address: GOWER STREET contact info |
UK (LONDON) | participant | 284˙600.00 |
| 10 |
Medicomp Gesellschaft fuer Versuchsplanung und Datenanlyse mbH
Organization address
address: Ordenslandstrasse 11 contact info |
DE (Olching) | participant | 269˙505.00 |
| 11 |
CAMPBELL CHARLES ASSOCIATES (2000)LIMITED
Organization address
address: STATION ROAD 48 contact info |
UK (STOKE D ABERNON) | participant | 242˙370.00 |
| 12 |
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
Organization address
address: 3 Avenue Victoria contact info |
FR (PARIS) | participant | 201˙720.00 |
| 13 |
UNIVERSITY OF DUNDEE
Organization address
address: Nethergate contact info |
UK (DUNDEE) | participant | 182˙640.00 |
| 14 |
FUNDACIO PRIVADA CLINIC PER A LA RECERCA BIOMEDICA
Organization address
address: CARRER ROSSELLO 149-153 contact info |
ES (BARCELONA) | participant | 181˙500.00 |
| 15 |
"THE SCHOOL OF PHARMACY, UNIVERSITY OF LONDON"
Organization address
address: Brunswick Square 29-39 contact info |
UK (LONDON) | participant | 164˙080.00 |
| 16 |
OSPEDALE PEDIATRICO BAMBINO GESU
Organization address
address: PIAZZA SAN ONOFRIO 4 contact info |
IT (ROMA) | participant | 154˙080.00 |
| 17 |
SERVICIO MADRILENO DE SALUD
Organization address
address: PLAZA CARLOS TRIAS BERTRAN 7 contact info |
ES (MADRID) | participant | 153˙640.00 |
| 18 |
Fondazione Stella Maris
Organization address
address: Viale del Tirreno 331 contact info |
IT (Pisa) | participant | 135˙660.00 |
| 19 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 56˙400.00 |
| 20 |
KATHOLIEKE UNIVERSITEIT LEUVEN
Organization address
address: Oude Markt 13 contact info |
BE (LEUVEN) | participant | 51˙600.00 |
| 21 |
WOCKHARDT UK LTD
Organization address
address: "ASH ROAD NORTH, WREXHAM INDUSTRIAL ESTATE" contact info |
UK (WREXHAM) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Second-generation antipsychotics are increasingly being prescribed to children and adolescents. Their use, however, is mostly off-label, and adequate and sufficient data about efficacy and particular safety are lacking. This proposal focuses on two indications, the use of risperidone in children and adolescents with conduct disorder who are not mentally retarded, and the use of risperidone in adolescents with schizophrenia. The objectives are to 1) perform a series of clinical studies that will provide sufficient information for a Paediatric Use Marketing Authorisation to be obtained for these indications; 2) address scientific questions about the moderating and/or mediating factors of the efficacy and safety of risperidone in children and adolescents, and 3) disseminate the knowledge acquired by the proposed studies to medical and mental health professionals, to patients and their families and society in general.'
Introduzione (Teaser)
Conduct disorder (CD) implies a recurrent violation of age-appropriate societal norms or rules. Children and adolescents consistently displaying such anti-social behaviour are placed on off-label antipsychotic medications such as risperidone.